JOSD1 drives hepatocellular carcinoma malignancy by modulating the ubiquitination-lactylation switch on PGAM1
Abstract
Background: Metabolic reprogramming is a hallmark of hepatocellular carcinoma (HCC), enabling rapid tumour growth and immune evasion. Protein post-translational modification (PTM) crosstalk is a critical regulator of cellular processes; however, its contribution to metabolic reprogramming in HCC remains unclear. Objective: To elucidate the function of the deubiquitinase JOSD1 in modulating PTM crosstalk and its impact on tumour glycolysis, progression and immunotherapy response in HCC. Design: We combined multi-omics analyses with functional and mechanistic studies in cell lines, animal models and patient samples to characterise JOSD1 and its downstream pathways in HCC. Results: JOSD1 was identified as a gene associated with glycolysis and correlated with a poor prognosis. Its over-expression promoted malignant phenotypes and enhanced glycolytic flux. Mechanistically, the JOSD1-AARS1 axis cooperatively regulates the ubiquitination-lactylation crosstalk at the K251 residue of PGAM1, thereby stabilising PGAM1, enhancing its enzymatic activity and promoting lactate accumulation. This metabolic shift impaired CD8 + T cell infiltration and function, promoting immune suppression. Therapeutically, liver-targeted inhibition of JOSD1 effectively suppressed tumour progression and synergised with anti-PD-1 therapy, leading to prolonged survival. Conclusion: The JOSD1-AARS1 axis regulates the ubiquitination-lactylation crosstalk on PGAM1, with JOSD1 acting as the critical upstream molecular switch that drives metabolic reprogramming and immune evasion in HCC. Targeting JOSD1 represents a promising therapeutic strategy to modulate tumour metabolism and improve immunotherapy efficacy.Keywords
Funding Information
- The Key R&D Program of Jiangxi Province (20223BBG71008)
- Jiangsu Provincial Frontier Technology Research and Development Program (BF2024053)
- the Zhanggong Science and Technology Plan Project (2023SF05)
- Jiangsu Provincial Medical Innovation Centre (CXZX202203)
- Ganzhou Science and Technology Project Young Talent Program (2022CXRC9712)
- Guangxi Key Reaserch and Development Program (GuikeAB25069034)
- Jiangsu Province Hospital High-level Talent Cultivation Program (CZ0121002010037)
- National Natural Science Foundation of China (82300684)
- National Natural Science Foundation of China (82460122)
- National Natural Science Foundation of China (82472862)
- National Natural Science Foundation of China (82472938)
- the 111 Center (D17011)
- Jiangsu Provincial Medical Key Laboratory (ZDXYS202201)
- the Ganzhou Talent Project (GZSQZG202301010)
- Natural Science Foundation of Jiangxi Province (20232ACB206006)
- Natural Science Foundation of Jiangxi Province (20242BAB23074)
This publication has 48 references indexed in Scilit:
- Lactylation in cancer: Current understanding and challengesCancer Cell, 2024
- The regulatory roles and clinical significance of glycolysis in tumorCancer Communications, 2024
- Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesisCell, 2024
- Thymidine kinase 1 drives hepatocellular carcinoma in enzyme-dependent and -independent mannersCell Metabolism, 2023
- Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinomaJournal of Hepatology, 2022
- Targeting PGAM1 in cancer: An emerging therapeutic opportunityEuropean Journal of Medicinal Chemistry, 2022
- The hallmarks of cancer metabolism: Still emergingCell Metabolism, 2022
- NAFLD-driven HCC: Safety and efficacy of current and emerging treatment optionsJournal of Hepatology, 2022
- Innate immune regulatory networks in hepatic lipid metabolismJournal of Molecular Medicine, 2019
- Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate EnvironmentsCell Metabolism, 2017